Rachna T Shroff, MD, MS

-
Medical Director, Clinical Trials Office
Associate Professor, Medicine
Interim Director, Arizona Clinical Trials Network
Associate Director of Clinical Investigations
Biography
Rachna T. Shroff, MD, MS, is an Associate Professor of Medicine and Chief of GI Medical Oncology as well as Leader of the Gastrointestinal Clinical Research Team at the University of Arizona Cancer Center. She is the Director of the UArizona Cancer Center Clinical Trials Office as well as the Director of the Arizona Clinical Trials Network (ACTN), and Vice Chair of Clinical Research for the Department of Medicine. She came to the Cancer Center from MD Anderson Cancer Center in Houston, TX where she served as faculty from 2010-2018 after completing her medical oncology fellowship there.
Dr. Shroff is a clinical and translational investigator focused on developing novel therapies for pancreatic and biliary cancers. She holds multiple positions nationally due to her expertise in these areas, including serving as the Hepatobiliary subcommittee Co-Chair for the Southwest Oncology Group (SWOG) and as a Program Committee member for GI ASCO. She also is a member of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. Dr. Shroff has led numerous clinical trials focusing on pancreaticobiliary tumors and is the national PI for SWOG 1815 which is investigating a triplet chemotherapy regimen as a potential new standard of care for biliary cancers. This is based on a phase 2 study she led that is now published in JAMA Oncology. Dr. Shroff has been invited to speak at national and international meetings on topics related to targeted therapies for pancreatic and biliary cancers and has numerous peer-reviewed publications in this area.
Cancer Focus
Dr. Shroff has focused her career on clinical and translational research in gastrointestinal malignancies. She has been principal investigator on a number of trials in pancreatic and biliary cancers. She has established herself as a leading expert in biliary cancer and is the national P.I. on a pivotal, phase III study through SWOG in this disease. Dr. Shroff has authored many peer-reviewed publications in these areas and she has been invited to give multiple platform presentations on pancreatic and biliary cancers across the world. In addition, she is the leader of the Gastrointestinal (GI) Oncology Disease Oriented Team at the Cancer Center. This comprehensive program includes weekly multidisciplinary tumor board meetings, bi-monthly research meetings, and research collaborations with the Developmental Therapeutics/Phase 1 Program. She currently serves as the Associate Dean of Clinical and Translational Research for the College of Medicine. She also has leadership roles as the Medical Director for both the Clinical Trials Office and Arizona Clinical Trials Network (ACTN) in the Cancer Center. She also has previously served as the chair of the Cancer Center Data Safety and Monitoring Board given her experience with trial design and safety. Her vision for the Section of GI Medical Oncology is to continue providing cutting-edge multidisciplinary care while developing a clinical trial portfolio that offers novel therapeutic options for all patients with GI malignancies.
Selected Publications
Mizrahi, J. D., R. Surana, J. W. Valle, and R. T. Shroff, "Pancreatic cancer.", Lancet, vol. 395, issue 10242, pp. 2008-2020, 2020 06 27. PMID: 32593337
Shroff, R. T., E. B. Kennedy, M. Bachini, T. Bekaii-Saab, C. Crane, J. Edeline, A. El-Khoueiry, M. Feng, M. H. G. Katz, J. Primrose, et al., "Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline.", J Clin Oncol, vol. 37, issue 12, pp. 1015-1027, 2019 04 20. PMID: 30856044
Shroff, R. T., A. Hendifar, R. R. McWilliams, R. Geva, R. Epelbaum, L. Rolfe, S. Goble, K. K. Lin, A. V. Biankin, H. Giordano, et al., "Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious Mutation.", JCO Precis Oncol, vol. 2018, 2018. PMCID: PMC6057747 PMID: 30051098
Javle, M., M. Lowery, R. T. Shroff, K. Heinz Weiss, C. Springfeld, M. J. Borad, R. K. Ramanathan, L. Goyal, S. Sadeghi, T. Macarulla, et al., "Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.", J Clin Oncol, vol. 36, issue 3, pp. 276-282, 2018 Jan 20. PMCID: PMC6075847 PMID: 29182496
Shroff, R. T., M. Yarchoan, A. O'Connor, D. Gallagher, M. L. Zahurak, G. Rosner, C. Ohaji, S. Sartorius-Mergenthaler, R. Parkinson, V. Subbiah, et al., "The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.", Br J Cancer, vol. 118, issue 2, pp. e2, 2018 01. PMCID: PMC5785753 PMID: 29315294
Rogers, J. E., R. M. Bolonesi, A. Rashid, K. M. Elsayes, M. G. Elbanan, L. Law, A. Kaseb, and R. T. Shroff, "Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy.", J Gastrointest Oncol, vol. 8, issue 2, pp. 347-351, 2017 Apr. PMCID: PMC5401851 PMID: 28480073
"Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.", Cancer Cell, vol. 32, issue 2, pp. 185-203.e13, 2017 08 14. PMCID: PMC5964983 PMID: 28810144
Shroff, R. T., J. Knox, and E. Dixon, "Consensus conference on gallbladder cancer.", HPB (Oxford), vol. 17, issue 8, pp. 664-5, 2015 Aug. PMCID: PMC4527850 PMID: 26172132